Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Increasing PrEP Use in High-Risk Social Networks of African-American MSM in Underserved Low-Risk Cities (SNAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03823209
Recruitment Status : Enrolling by invitation
First Posted : January 30, 2019
Last Update Posted : August 18, 2021
Sponsor:
Information provided by (Responsible Party):
Jeffrey Kelly, Medical College of Wisconsin

Brief Summary:
This study evaluates the use of a social-network approach to encourage African-American men who have sex with men (AAMSM) to adopt pre-exposure prophylaxis (PrEP) to prevent HIV infection. Thirty-six networks of AAMSM will be recruited in Milwaukee, WI, and Cleveland, OH. Half of these networks will have their leaders trained to endorse PrEP to their social network members, and the other half will be given brief HIV prevention counseling.

Condition or disease Intervention/treatment Phase
Human Immunodeficiency Virus Behavioral: Social Network Behavioral: Brief HIV Prevention Counseling Not Applicable

Detailed Description:

Pre-exposure prophylaxis (PrEP) regimens greatly reduce the likelihood that high-risk uninfected men who have sex with men (MSM) will contract HIV infection. Although this protective benefit has been unequivocally established in clinical trials, the number of high-risk men on PrEP remains far below the threshold needed to substantially reduce HIV incidence. This is especially true outside of the country's largest cities. Novel approaches are needed to increase PrEP use among high-risk racial minority MSM in these neglected cities.

This study will recruit 36 sociocentric social networks of high-risk young racial minority MSM, 18 networks per city (total n=36 networks x 14 anticipated recruited members per network = 504 participants). Participants will complete measures assessing baseline PrEP use; knowledge, attitudes, perceived norms, intentions, and stage of readiness for PrEP; sexual risk practices and substance use; and prior or current ART use. Participants will also complete measures used to identify each network's leaders.

Networks will be randomized in equal numbers in each city to comparison or intervention conditions. All study participants will receive individual baseline counseling about risk reduction and PrEP, with referral offered to clinics prescribing PrEP. Members of the 18 experimental condition networks will also receive the social network PrEP intervention being tested in the study. In it, cadres of leaders in each network-selected based on their leadership position within the network and their own openness to PrEP-will attend a 5-session intervention that trains, engages, and supports network leaders in communicating to friends accurate information about PrEP and its availability; corrects PrEP misconceptions and negative stereotypes; endorses PrEP use and its benefits; and strengthens friends' attitudes, intentions, perceived peer norms, and self-efficacy regarding PrEP as a personal HIV protective strategy. Two additional booster sessions spaced monthly will support maintenance of leaders' efforts in talking with friends in their network about the benefits of PrEP, as well as where and how to access it.

At 6- and 15-month followup points, all study participants will complete the same behavioral measures that were administered at baseline, as well as measures of intervention exposure.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Increasing PrEP Use in High-Risk Social Networks of African-American MSM in Underserved Low-Risk Cities
Actual Study Start Date : January 24, 2019
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : July 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Social Network Approach

Participants will receive brief HIV counseling at baseline visit.

Leaders of social networks will be determined using data from participants. These leaders will then be invited to attend a 5-session small-group training that will teach them how to communicate the benefits of PrEP to their social network members.

All social network members will be asked about intervention exposure at 6- and 15-month followups.

Behavioral: Social Network
Leaders of social networks will be statistically determined. Over 5 small-group training sessions, these leaders will be trained to communicate to their social network members accurate information about PrEP and its availability; correct PrEP misconceptions and negative stereotypes; endorse PrEP use and its benefits; and strengthen friends' attitudes, intentions, perceived peer norms, and self-efficacy regarding PrEP as a personal HIV protective strategy.

Behavioral: Brief HIV Prevention Counseling
Participants will receive brief (15-minute) counseling on how to prevent HIV infection.

Active Comparator: Comparison
Participants will receive brief HIV counseling at baseline visit.
Behavioral: Brief HIV Prevention Counseling
Participants will receive brief (15-minute) counseling on how to prevent HIV infection.




Primary Outcome Measures :
  1. Self-report of pre-exposure prophylaxis (PrEP) use [ Time Frame: 6 and 15 months ]
    Change in self-reported PrEP use


Secondary Outcome Measures :
  1. Pre-Exposure Prophylaxis (PrEP) Knowledge [ Time Frame: 6 and 15 months ]

    PrEP Knowledge: 13 items in scale, items are added to determine score, with higher scores indicating greater knowledge

    Scale taken from Walsh, J.L. (2018). Applying the Information-Motivation-Behavioral Skills Model to Understand PrEP Intentions and Use Among Men Who Have Sex with Men. AIDS and Behavior.


  2. Pre-Exposure Prophylaxis Attitudes [ Time Frame: 6 and 15 months ]

    PrEP Attitudes: 5 items in scale, items are averaged to determine score, with higher scores indicating more positive attitudes

    Scale taken from Walsh, J.L. (2018). Applying the Information-Motivation-Behavioral Skills Model to Understand PrEP Intentions and Use Among Men Who Have Sex with Men. AIDS and Behavior.


  3. Pre-Exposure Prophylaxis Norm Perceptions [ Time Frame: 6 and 15 months ]

    PrEP Norm Perceptions: 6 items in scale, items are averaged to determine score, with higher scores indicating more favorable norms

    Scale taken from Walsh, J.L. (2018). Applying the Information-Motivation-Behavioral Skills Model to Understand PrEP Intentions and Use Among Men Who Have Sex with Men. AIDS and Behavior.


  4. Pre-Exposure Prophylaxis Intentions [ Time Frame: 6 and 15 months ]

    PrEP Intentions: 3 items in scale, items are averaged to determine score, with higher scores indicating greater intentions to use PrEP

    Scale taken from Walsh, J.L. (2018). Applying the Information-Motivation-Behavioral Skills Model to Understand PrEP Intentions and Use Among Men Who Have Sex with Men. AIDS and Behavior.


  5. Pre-Exposure Prophylaxis Self-Efficacy [ Time Frame: 6 and 15 months ]

    PrEP Self-Efficacy: 8 items in scale, items are averaged to determine score, with higher scores indicating greater self-efficacy for PrEP use.

    Scale taken from Walsh, J.L. (2018). Applying the Information-Motivation-Behavioral Skills Model to Understand PrEP Intentions and Use Among Men Who Have Sex with Men. AIDS and Behavior.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

INDIVIDUALS:

  1. Age 16 or older
  2. For the seed only, self-report of HIV-negative serostatus or unknown serostatus
  3. Except for the seed, being named as a friend by an already-enrolled participant
  4. Male at birth
  5. Sex with at least one male partner in the past 12 months

NETWORKS

  1. More than 49% of the seed's eligible friends agree to participate
  2. More than 49% of all network members self-report they are HIV-negative at baseline

Exclusion Criteria:

INDIVIDUALS:

  1. Age 15 or younger
  2. For the seed only, self-report of HIV-positive serostatus
  3. Except for the seed, not being named as a friend by an already-enrolled participant
  4. Not male at birth
  5. No report of sex with at least one male partner in the past 12 months

NETWORKS

  1. Less than 50% of the seed's eligible friends agree to participate
  2. Less than 50% of all network members self-report they are HIV-negative at baseline

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03823209


Locations
Layout table for location information
United States, Ohio
AIDS TaskForce of Greater Cleveland
Cleveland, Ohio, United States, 44113
United States, Wisconsin
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53202
Sponsors and Collaborators
Medical College of Wisconsin
Investigators
Layout table for investigator information
Principal Investigator: Jeffrey A. Kelly, PhD Medical College of Wisconsin
Principal Investigator: Yuri A. Amirkhanian, PhD Medical College of Wisconsin
  Study Documents (Full-Text)

Documents provided by Jeffrey Kelly, Medical College of Wisconsin:
Informed Consent Form  [PDF] April 1, 2019

Publications of Results:
Layout table for additonal information
Responsible Party: Jeffrey Kelly, Professor, Medical College of Wisconsin
ClinicalTrials.gov Identifier: NCT03823209    
Other Study ID Numbers: PRO00029359
First Posted: January 30, 2019    Key Record Dates
Last Update Posted: August 18, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jeffrey Kelly, Medical College of Wisconsin:
Pre-exposure prophylaxis (PrEP)
Additional relevant MeSH terms:
Layout table for MeSH terms
Acquired Immunodeficiency Syndrome
HIV Infections
Immunologic Deficiency Syndromes
Immune System Diseases
Blood-Borne Infections
Communicable Diseases
Infections
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Slow Virus Diseases